Shanghai Shyndec Pharmaceutical News

Sinopharm Hyundai (600420.SH) announced first-quarter results, net profit of 331 million yuan, up 84.83% year-on-year

According to Zhitong Finance App News, Sinopharm Hyundai (600420.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 3.123 billion yuan, a year-on-year decrease of 8.6%; net profit attributable to shareholders of listed companies was 331 million yuan, an increase of 84.83% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 326 million yuan, an increase of 91.04% year on year; basic earnings per share were 0.2470 yuan.

Zhitong FinanceApr 29 18:49

Sinopharm Hyundai (600420): The reform of the central enterprise chemical platform integrating API formulations is expected to improve efficiency and profitability

Sinopharm Hyundai is a chemical industry platform under the Sinopharm Group. After years of development and integration, it has formed a powerful chemical platform industrial enterprise with integrated intermediate API formulations. We believe that there is room to improve the company's current profit level and improve quality with the help of central enterprises

信達證券Apr 26 00:00

Sinopharm Hyundai (600420.SH): The company's current hypoglycemic drugs include engagliflozin tablets

Gelonghui, April 24 | Sinopharm Hyundai (600420.SH) said on the investor interactive platform that the company currently has glucose-lowering drugs such as engliflozin tablets, as well as the active ingredients acarbose and voglibose. None of the above drugs currently have any weight-loss-related indications.

Gelonghui FinanceApr 24 15:36

Sinopharm Hyundai (600420.SH): Injectable ceftriaxone passes consistent evaluation of generic drug quality and efficacy

Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...

Zhitong FinanceApr 19 16:15

Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Rongsheng Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its empaglif

MT NewswiresApr 16 17:11

Sinopharm Hyundai (600420.SH): Empagliflozin tablets obtained drug registration certificate

Gelonghui, April 15 | Sinopharm Hyundai (600420.SH) announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for englizine tablets approved and issued by the State Drug Administration. Empagliflozin reduces the ability of the kidneys to recycle glucose back into the bloodstream and excretes sugar from the body through urine, which helps reduce patients' blood sugar levels.

Gelonghui FinanceApr 15 17:18

Express News | Sinopharm Hyundai: Net profit increased 78.55% to 89.71% in the first quarter of 2024

BreakingsApr 12 16:26

Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials

China's food and drug administration granted marketing approval to Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Yixin Pharmaceutical's trifluridine tipiracil preparation products,

MT NewswiresApr 10 16:48

Express News | Sinopharm Hyundai: The holding subsidiary received a notice of approval for the marketing application of chemical raw materials

BreakingsApr 9 16:39

Sinopharm Hyundai (600420.SH) released 2023 results, net profit of 692 million yuan, up 10.21% year on year

Sinopharm Hyundai (600420.SH) released its 2023 annual report, achieving revenue of 12.07 billion yuan,...

Zhitong FinanceMar 29 19:07

China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification From Australian Regulator

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Zhijun (Shenzhen) Pharmaceutical, received certification from Australia's Therapeutic Goods Administration for its production bases after

MT NewswiresMar 27 17:58

Express News | Sinopharm Hyundai: The holding subsidiary passed Australian TGA-GMP certification

BreakingsMar 26 16:48

Express News | Sinopharm Hyundai: Wholly-owned subsidiary remifentanil hydrochloride for injection passed generic drug consistency evaluation

BreakingsMar 15 17:10

Express News | Sinopharm Hyundai: Tranexamic acid injection passed the consistent evaluation of generic drug quality and efficacy

BreakingsMar 12 17:50

Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Qinghai Biopharmaceutical Factory, received approval from China's Ministry of Agriculture and Rural Affairs to produce and market its vaccine again

MT NewswiresMar 7 13:43

Express News | Sinopharm Hyundai: Sun Company obtained approval number for veterinary drug products

BreakingsMar 6 16:51

Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation

Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Weiqida Pharmaceutical's cefotaxime sodium for injection passed the quality and efficacy consistency evaluation of China's National Me

MT NewswiresFeb 21 11:52

Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Yixin Pharmaceutical, received notice from China's National Medical Products Administration that its dacarbazine for injection passed the

MT NewswiresFeb 20 16:56

Express News | Sinopharm Hyundai: Wholly-owned subsidiary cefotaxime sodium for injection passed generic drug consistency evaluation

BreakingsFeb 20 16:16

Express News | Sinopharm Hyundai: The holding subsidiary's injectable dacarbazine passed the generic drug consistency evaluation

BreakingsFeb 19 16:12